Back to search

Article

Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

2024-01-04

Abstract excerpt

Enzalutamide is a second-generation androgen-receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker after enzalutamide administration. A retrospective subgroup analysis and prognostic survey of 43 patients with mCRPC and bone metastases,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
055eca9f-f1f6-5aed-af4d-3e3f661c6f16
DOI
10.20944/preprints202401.0336.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by EnzalutamideDOI 10.20944/preprints202401.0336.v1
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysisSemantic proximity
Bone Scan Index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastasesSemantic proximity
Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer.Semantic proximity
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.Semantic proximity
Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate CancerSemantic proximity
VALIDATION OF PROGRESS, A SIMPLE MACHINE-LEARNING DERIVED RISK STRATIFICATION SCORE FOR CASTRATION-RESISTANT PROSTATE CANCERSemantic proximity
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.Semantic proximity
AR-V7 Positivity Varies with Circulating Tumor Cell (CTC) Enrichment and Novel CTC Enrichment Is Able to Reduce AR-V7 False PositivitySemantic proximity
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.Semantic proximity
Early treatment outcome prediction in metastatic castration-resistant prostate cancer utilizing 3-month tumor growth rate ( <i>g</i> -rate) based machine learning modelSemantic proximity
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.Semantic proximity
Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patientsSemantic proximity
Select a neighboring publication to make it the new centre.